|
Patent landscape, scope, and claims: |
United States Patent 3,546,226: What Is Claimed, What It Covers, and How Strong Is the Patent Estate?
United States Patent 3,546,226 has an enforceable scope that is anchored to its independent claim structure and the specific product-by-process or composition boundaries used in the claim set. A complete, claim-by-claim scope map, including literal and doctrine-of-equivalents coverage, cannot be produced from the information provided because the user message does not include the patent’s claim text.
What does US Patent 3,546,226 claim, and what is the practical scope of coverage?
A scope analysis requires the exact language of the independent claims and all dependent claims. Without the full claim set, coverage cannot be characterized for:
- active ingredient identity or formula structure
- composition ranges (weight %, mol %, particle size, viscosity, pH, etc.)
- dosage form (tablet, capsule, injection, sustained release, etc.)
- method steps (mixing order, temperatures, catalysts, purification, sterilization)
- product-by-process limitations
- optional constituents and how they’re claimed
How do independent claims define the boundary of infringement risk?
Independent claims typically define infringement risk through:
- claim preambles that limit the category (composition vs. method vs. kit)
- structural limitations (chemical structure, functional group counts)
- numerical ranges
- process conditions for product-by-process claims
- “consisting of” or “comprising” transition language effects
How do dependent claims narrow the scope?
Dependent claims narrow scope by adding:
- preferred embodiments or sub-ranges
- additional components (stabilizers, buffers, excipients, salts)
- additional manufacturing steps
- additional method-of-use limitations
Which later patents build on or circumvent US 3,546,226?
A landscape assessment requires identifying:
- citing and family members
- continuation/divisional trail
- later patents on improvements in the same technology space
- obviousness or double patenting indicators
- improvements in formulation, manufacturing, and use
Without the subject matter of the claims (or the drug/technology tied to the patent), the landscape cannot be mapped.
When does US 3,546,226 expire, and what exclusivity timelines apply in the US?
US patent term depends on:
- filing date (pre- and post-URAA)
- whether term adjustment applies
- whether PTA was granted
- any regulatory exclusivity that was later obtained for the drug using the invention
- whether the patent issued from continuations with different filing dates
A timeline with specific expiration dates requires the patent’s filing date and prosecution/term data.
What patents are listed in the Orange Book for the corresponding drug, and what is the release/exclusivity status?
Orange Book mapping requires:
- the FDA application number (NDA/BLA/ANDA link)
- listed active ingredients and dosage forms
- patent numbers listed per NDA/BLA
- expiration dates and “Orange Book” exclusivity codes
No NDA/BLA identifier or drug name is provided, so Orange Book status cannot be determined.
How strong is the patent estate for US 3,546,226 (validity, enforceability, and claim construction)?
Strength scoring depends on:
- prosecution history (claim amendments, rejections, allowance rationale)
- prior art cited against the application
- whether claims were narrowed to overcome novelty or obviousness
- whether any of the claims were invalidated, limited, or disclaimed in reexamination/inter partes proceedings
- whether there is active litigation affecting enforceability
No prosecution or litigation record details are included.
What generic entry risks exist if US 3,546,226 is asserted against an ANDA?
A generic entry risk analysis typically requires:
- which claim types are asserted (composition, method-of-use, manufacturing)
- whether the generic product is designed around by omitting claimed components or conditions
- whether the claim is infringed by product equivalence or only by literal product-by-process steps
- whether the claim is listed in the Orange Book for the relevant NDA
No drug application or ANDA context is supplied.
How does US 3,546,226 compare with competing patents in the same therapeutic or formulation class?
A meaningful comparison needs:
- a defined competitive set (other assignees and their families)
- which jurisdictions (US only vs. EP/WO/CN/JPO)
- whether the prior art landscape shows convergence or divergent claim strategy
No drug/technology class is provided.
Patent litigation: Has US 3,546,226 been asserted or challenged (e.g., Paragraph IV)?
Litigation assessment requires:
- case captions, courts, docket numbers
- asserted claim numbers
- outcome status (dismissed, settled, invalidated, consent judgments)
- settlement terms where available (carve-outs, launch dates, non-infringement covenants)
No litigation history is provided.
What formulations, dosage forms, or methods are protected by US 3,546,226?
Protection can be product-type specific (e.g., solid dosage vs. injectable vs. sustained release) and could be:
- composition-only (ingredient and ratios)
- method-of-manufacture (mixing and processing conditions)
- method-of-use (indication or treatment regimen)
- combination coverage (active + excipient package)
The claim text is required to determine which of these applies.
Key Takeaways
- A claim-scope analysis of US Patent 3,546,226 cannot be completed without the patent’s actual claim text.
- Deliverables normally produced for this patent type include claim-by-claim infringement mapping, expiration timeline, Orange Book listing verification, and validity/estoppel strength scoring, but each requires claim language and the linked FDA product context.
FAQs
- What is the practical difference between product claims and method claims for infringement risk under US Patent 3,546,226?
- How do product-by-process limitations affect design-around strategies for ANDA applicants?
- How is patent term determined for pre-URAA US patents like 3,546,226 when no regulatory exclusivity is known?
- What evidence from prosecution history most often controls claim construction for older composition patents?
- When can Orange Book “listed” patents still be avoided through non-infringing formulation design, even if the listed patent remains valid?
References
- United States Patent No. 3,546,226.
More… ↓
⤷ Start Trial
|
